Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj
Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj
Sponsor: Kang Stem Biotech Co., Ltd.
Listed as NCT03106259, this observational or N/A phase trial focuses on Rheumatoid Arthritis and remains ongoing. Sponsored by Kang Stem Biotech Co., Ltd., it has been updated 10 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Active Not Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Active Not Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Active Not Recruiting NA
-
Oct 2017 — Mar 2018 [monthly]
Active Not Recruiting NA
-
May 2017 — Oct 2017 [monthly]
Active Not Recruiting NA
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kang Stem Biotech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .